Aura Biosciences is restructuring its operations under recently appointed Chief Executive Officer Natalie Holles, shifting its focus toward ocular oncology while reducing its workforce by approximately 20% and making multiple changes to its executive leadership team.
Holles, who assumed the CEO role in April, inherited a company developing precision therapies for solid tumors. At the time, Aura was advancing its lead candidate, belzupacap sarotalocan (bel-sar), through a Phase 3 study in adults with early choroidal melanoma while also conducting earlier-stage clinical studies in other disease areas, including non-muscle invasive bladder cancer (NMIBC).
Company Shifts Resources Toward Eye Cancer Programs
After taking over as CEO, Holles repositioned Aura as an ocular oncology company. While the company reported what it described as an encouraging early clinical profile for bel-sar in an NMIBC study, it has decided to reduce investment in that program and concentrate resources on eye cancer indications.
Aura plans to continue collecting data in its Phase 1b/2 NMIBC trial through the protocol-defined 12-month follow-up period. According to the company, this approach will preserve future strategic options while allowing it to direct resources toward ocular oncology development programs.
The company is now prioritizing bel-sar in eye cancer indications, including metastases to the choroid and cancers affecting the ocular surface. Aura said that funds made available through the reduced focus on NMIBC will be used to support “more robust clinical data generation” for ocular oncology indications.
Enrollment Completed in Phase 3 Choroidal Melanoma Study
A key development for Aura’s lead program is the completion of patient enrollment in the Phase 3 CoMpass trial evaluating bel-sar in early choroidal melanoma. Aura had previously described the study as evaluating bel-sar as a vision-sparing therapy in adults with the disease.
With enrollment complete, the company remains on track to report topline results from the trial’s 15-month primary endpoint in the second half of 2027.
Workforce Reduction and Organizational Realignment
As part of the restructuring, Aura is reducing its workforce by about 20%. The company had 113 full-time employees as of Feb. 28, meaning the reduction could affect approximately 23 employees.
Aura disclosed that costs and cash payments associated with the workforce reduction and organizational realignment are expected to range between $2.9 million and $3.2 million, with most of those expenses anticipated during the third quarter.
The company stated that the workforce reduction “resulted in the loss of longer-term employees, the loss of institutional knowledge and expertise, and the reallocation and combination of certain roles and responsibilities across the organization, all of which could adversely affect our operations.”
Executive Team Changes Accompany Strategic Shift
The restructuring also includes several changes within Aura’s executive leadership team. Tony Gibney is stepping down from his position as chief financial and business officer, while Conor Kilroy is leaving his role as chief legal officer. Mark Plavsic has also departed as chief technology officer.
At the same time, Aura has appointed Susan Abu-Absi as chief operating officer, Erica Kratz as chief regulatory and quality officer, and Julie Person as chief people officer. An existing employee will serve as interim chief financial officer.
Alongside the operational changes, Aura projects that its revised spending plans will extend its cash runway into the first half of 2029, compared with the second half of 2028 under its previous plan.
Aura Biosciences Reshapes Its Strategy
Aura Biosciences is narrowing its focus on ocular oncology as the biotechnology company works to prioritize its clinical programs and manage resources more efficiently. The restructuring includes a workforce reduction of approximately 20%.
The decision allows Aura Biosciences to concentrate its resources on programs with the greatest potential while reducing operating costs.
Aura Biosciences Prioritizes Ocular Oncology
The strategic shift puts ocular oncology at the center of Aura Biosciences’ development strategy. The company is working to advance therapies designed to address serious eye cancers and other difficult-to-treat ocular tumors.
Aura Biosciences Advances Its Pipeline
The restructuring gives Aura Biosciences an opportunity to direct greater attention toward its most advanced ocular oncology candidates. The company will need to demonstrate continued clinical progress to validate its strategy and support future development.
The focus on ocular oncology also reflects Aura Biosciences’ broader goal of developing targeted therapies for cancers where treatment options remain limited.
Aura Biosciences Looks Ahead
The restructuring marks an important stage for Aura Biosciences as it balances clinical ambitions with financial discipline. The company’s ability to advance its priority programs efficiently will be a key factor in determining its next phase of growth.
For Aura Biosciences, maintaining clinical momentum while operating with a smaller workforce will remain an important challenge as it moves forward.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
